Selective clinical and immune response of the oligoclonal autoreactive T cells in Omenn patients after cyclosporin A treatment

A. Lev, A. J. Simon, N. Amariglio, G. Rechavi, R. Somech*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The immunological hallmark of Omenn syndrome (OS) is the expansion and activation of an oligoclonal population of autoreactive T cells. These cells should be controlled rapidly by immunosuppressive agents, such as cyclosporin A (CsA), to avoid tissue infiltration and to improve the general outcome of the patients. Here we studied the clinical and the immune response to CsA in two Omenn patients and also examined the gene expression profile associated with good clinical response to such therapy. T cell receptor diversity was studied in cells obtained from OS patients during CsA therapy. Characterization of gene expression in these cells was carried out by using the TaqMan low-density array. One patient showed complete resolution of his symptoms after CsA therapy. The other patient showed selective response of his oligoclonal T cell population and combination therapy was required to control his symptoms. Transcriptional profile associated with good clinical response to CsA therapy revealed significant changes in 26·6% of the tested genes when compared with the transcriptional profile of the cells before treatment. Different clinical response to CsA in two OS patients is correlated with their immunological response. Varying clonal expansions in OS patients can cause autoimmune features and can respond differently to immunosuppressive therapy; therefore, additional treatment is sometimes indicated. CsA for OS patients causes regulation of genes that are involved closely with self-tolerance and autoimmunity.

Original languageEnglish
Pages (from-to)338-345
Number of pages8
JournalClinical and Experimental Immunology
Volume167
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Keywords

  • Autoimmunity
  • Cyclosporin A
  • Immunodeficiency
  • Omenn
  • SCID

Fingerprint

Dive into the research topics of 'Selective clinical and immune response of the oligoclonal autoreactive T cells in Omenn patients after cyclosporin A treatment'. Together they form a unique fingerprint.

Cite this